Gene info: ID 6532

Gene: SLC6A4

GENE ID: 6532

Description: solute carrier family 6 member 4

Gene type: protein-coding

Location: 17q11.2

dbXrefs: Ensembl:ENSG00000108576 MIM:182138 Vega:OTTHUMG00000132751 UniprotKB:P31645

RefSeq: NG_011747.2

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: CD|OD|ND|AD

# Publications: 63

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 1.402e-1 (AD) 4.378e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
TDRD6	0.544
ALDH8A1	0.542
TSSK3	0.528
NAA16	0.528
MSANTD2	0.521
POGLUT1	0.52
FSD2	0.511
PRPF39	0.511
NAALAD2	0.507
LSMEM1	0.506

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
LHFPL1	-0.349
C16orf74	-0.292
ADIG	-0.29
WNT7B	-0.278
GGACT	-0.273
TNNT1	-0.273
CYP11A1	-0.271
ACSM5	-0.269
DIAPH3	-0.268
SARDH	-0.265

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00215	Citalopram	Small Molecule	59729-33-8	Approved	Transporter
DB01079	Tegaserod	Small Molecule	145158-71-0	Approved\|Investigational\|Withdrawn	Transporter
DB01454	Midomafetamine	Small Molecule	42542-10-9	Experimental\|Illicit\|Investigational	Transporter
DB06684	Vilazodone	Small Molecule	163521-12-8	Approved	Transporter
DB09194	Etoperidone	Small Molecule	52942-31-1	Withdrawn	Transporter
DB00176	Fluvoxamine	Small Molecule	54739-18-3	Approved\|Investigational	Target
DB00182	Amphetamine	Small Molecule	300-62-9	Approved\|Illicit\|Investigational	Target
DB00191	Phentermine	Small Molecule	122-09-8	Approved\|Illicit	Target
DB00193	Tramadol	Small Molecule	27203-92-5	Approved\|Investigational	Target
DB00215	Citalopram	Small Molecule	59729-33-8	Approved	Target
DB00285	Venlafaxine	Small Molecule	93413-69-5	Approved	Target
DB00289	Atomoxetine	Small Molecule	83015-26-3	Approved	Target
DB00321	Amitriptyline	Small Molecule	50-48-6	Approved	Target
DB00344	Protriptyline	Small Molecule	438-60-8	Approved	Target
DB00370	Mirtazapine	Small Molecule	85650-52-8	Approved	Target
DB00408	Loxapine	Small Molecule	1977-10-2	Approved	Target
DB00422	Methylphenidate	Small Molecule	113-45-1	Approved\|Investigational	Target
DB00454	Pethidine	Small Molecule	57-42-1	Approved	Target
DB00458	Imipramine	Small Molecule	50-49-7	Approved	Target
DB00472	Fluoxetine	Small Molecule	54910-89-3	Approved	Target
DB00476	Duloxetine	Small Molecule	116539-59-4	Approved	Target
DB00514	Dextromethorphan	Small Molecule	125-71-3	Approved	Target
DB00540	Nortriptyline	Small Molecule	72-69-5	Approved	Target
DB00543	Amoxapine	Small Molecule	14028-44-5	Approved	Target
DB00574	Fenfluramine	Small Molecule	458-24-2	Approved\|Illicit\|Investigational\|Withdrawn	Target
DB00579	Mazindol	Small Molecule	22232-71-9	Approved\|Investigational	Target
DB00656	Trazodone	Small Molecule	19794-93-5	Approved\|Investigational	Target
DB00661	Verapamil	Small Molecule	52-53-9	Approved	Target
DB00715	Paroxetine	Small Molecule	61869-08-7	Approved\|Investigational	Target
DB00726	Trimipramine	Small Molecule	739-71-9	Approved	Target
DB00805	Minaprine	Small Molecule	25905-77-5	Approved	Target
DB00852	Pseudoephedrine	Small Molecule	90-82-4	Approved	Target
DB00907	Cocaine	Small Molecule	50-36-2	Approved\|Illicit	Target
DB00988	Dopamine	Small Molecule	51-61-6	Approved	Target
DB01104	Sertraline	Small Molecule	79617-96-2	Approved	Target
DB01105	Sibutramine	Small Molecule	106650-56-0	Approved\|Illicit\|Investigational\|Withdrawn	Target
DB01114	Chlorphenamine	Small Molecule	132-22-9	Approved	Target
DB01142	Doxepin	Small Molecule	1668-19-5	Approved\|Investigational	Target
DB01149	Nefazodone	Small Molecule	83366-66-9	Approved\|Withdrawn	Target
DB01151	Desipramine	Small Molecule	50-47-5	Approved\|Investigational	Target
DB01175	Escitalopram	Small Molecule	128196-01-0	Approved\|Investigational	Target
DB01191	Dexfenfluramine	Small Molecule	3239-44-9	Approved\|Illicit\|Investigational\|Withdrawn	Target
DB01242	Clomipramine	Small Molecule	303-49-1	Approved\|Investigational	Target
DB01363	Ephedra	Small Molecule	-	Approved\|Nutraceutical\|Withdrawn	Target
DB01442	MMDA	Small Molecule	13674-05-0	Experimental\|Illicit	Target
DB01454	Midomafetamine	Small Molecule	42542-10-9	Experimental\|Illicit\|Investigational	Target
DB01472	4-Methoxyamphetamine	Small Molecule	64-13-1	Experimental\|Illicit	Target
DB01577	Methamphetamine	Small Molecule	537-46-2	Approved\|Illicit	Target
DB04821	Nomifensine	Small Molecule	24526-64-5	Withdrawn	Target
DB04832	Zimelidine	Small Molecule	56775-88-3	Withdrawn	Target
DB04836	Amineptine	Small Molecule	57574-09-1	Illicit\|Withdrawn	Target
DB04889	Bicifadine	Small Molecule	71195-57-8	Investigational	Target
DB04896	Milnacipran	Small Molecule	92623-85-3	Approved\|Investigational	Target
DB05422	OPC-14523	Small Molecule	-	Investigational	Target
DB05688	CRx-119	Small Molecule	-	Investigational	Target
DB06148	Mianserin	Small Molecule	24219-97-4	Approved\|Investigational	Target
DB06156	Tesofensine	Small Molecule	195875-84-4	Investigational	Target
DB06204	Tapentadol	Small Molecule	175591-23-8	Approved	Target
DB06700	Desvenlafaxine	Small Molecule	93413-62-8	Approved\|Investigational	Target
DB06701	Dexmethylphenidate	Small Molecule	40431-64-9	Approved\|Investigational	Target
DB08839	Serotonin	Small Molecule	50-67-9	Investigational\|Nutraceutical	Target
DB08918	Levomilnacipran	Small Molecule	96847-54-0	Approved\|Investigational	Target
DB09016	Butriptyline	Small Molecule	35941-65-2	Approved	Target
DB09068	Vortioxetine	Small Molecule	508233-74-7	Approved\|Investigational	Target
DB09167	Dosulepin	Small Molecule	113-53-1	Approved	Target
DB09186	Nisoxetine	Small Molecule	53179-07-0	Experimental	Target
DB09195	Lorpiprazole	Small Molecule	108785-69-9	Approved	Target
DB09225	Zotepine	Small Molecule	26615-21-4	Approved\|Investigational\|Withdrawn	Target
DB09289	Tianeptine	Small Molecule	72797-41-2	Approved\|Investigational	Target
DB12305	Dasotraline	Small Molecule	675126-05-3	Investigational	Target

ID	Drug Name	Action	PubMed
C015068	1-(3-chlorophenyl)piperazine	SLC6A4 protein affects the susceptibility to 1-(3-chlorophenyl)piperazine	25522398
C000592273	1-phenyl-2-(1-pyrrolidinyl)-1-pentanone	1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
C000592273	1-phenyl-2-(1-pyrrolidinyl)-1-pentanone	1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
C111118	2',3,3',4',5-pentachloro-4-hydroxybiphenyl	"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of SLC6A4 mRNA"	19114083
C569113	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
C569113	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
C014024	2,4,5,2',4',5'-hexachlorobiphenyl	"2,4,5,2',4',5'-hexachlorobiphenyl results in increased expression of SLC6A4 mRNA"	23146750
C079321	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
C079321	2-(4-bromo-2,5-dimethoxyphenyl)ethylamine	"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
C000595926	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine	"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
C000595926	2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine	"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
C554181	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
C554181	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
C069723	2beta-carbomethoxy-3beta-(4-iodophenyl)tropane	2beta-carbomethoxy-3beta-(4-iodophenyl)tropane binds to and results in decreased activity of SLC6A4 protein	16272152
C069723	2beta-carbomethoxy-3beta-(4-iodophenyl)tropane	2beta-carbomethoxy-3beta-(4-iodophenyl)tropane binds to SLC6A4 protein	15972295
C025946	3-methyladenine	"3-methyladenine inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein]"	26610922
C008745	4,4'-bisphenol F	"4,4'-bisphenol F results in decreased expression of SLC6A4 mRNA"	26186136
C009505	4,4'-diaminodiphenylmethane	"4,4'-diaminodiphenylmethane results in increased expression of SLC6A4 protein"	26116029
C079549	4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine	SLC6A4 results in increased susceptibility to 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine	18581099
C040639	4-fluoroamphetamine	4-fluoroamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
C040639	4-fluoroamphetamine	4-fluoroamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
C060169	4-methoxymethamphetamine	4-methoxymethamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
C060169	4-methoxymethamphetamine	4-methoxymethamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
C000608250	5-(2-aminopropyl)benzofuran	5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
C000608250	5-(2-aminopropyl)benzofuran	5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D000082	Acetaminophen	Acetaminophen results in increased activity of SLC6A4 protein	10849027
D019386	Alendronate	Alendronate affects the expression of SLC6A4 mRNA	16079270
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of SLC6A4 mRNA	16483693
D003913	Dextroamphetamine	SLC6A4 gene polymorphism affects the susceptibility to Dextroamphetamine	16966188
D000661	Amphetamine	Amphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D000661	Amphetamine	Amphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of SLC6A4 mRNA	24449571
D000068180	Aripiprazole	Aripiprazole binds to SLC6A4 protein	21823597
D001151	Arsenic	Arsenic results in increased expression of SLC6A4 mRNA	18315880
D000069059	Atorvastatin Calcium	Atorvastatin Calcium inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 protein]	17575010
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of SLC6A4 mRNA	26238291
D012369	2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-	"2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein]"	25370842
D004958	Estradiol	[Estradiol co-treated with Progesterone] affects the reaction [SLC6A4 promoter polymorphism affects the reaction [Citalopram results in increased expression of PRL protein]]	21843009
D004958	Estradiol	[Estradiol co-treated with Fluoxetine] results in increased expression of SLC6A4 mRNA	21382399
D004958	Estradiol	[Estradiol co-treated with Sertraline] affects the expression of SLC6A4 mRNA	18650020
D004958	Estradiol	Estradiol promotes the reaction [Sertraline results in increased expression of SLC6A4 mRNA]	18650020
D004958	Estradiol	Estradiol results in increased expression of SLC6A4 mRNA	18650020\|2138239
D015306	Biogenic Monoamines	1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
D015306	Biogenic Monoamines	"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
D015306	Biogenic Monoamines	"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
D015306	Biogenic Monoamines	4-fluoroamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	4-methoxymethamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	Amphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	Cocaine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	Fluoxetine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D015306	Biogenic Monoamines	"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
D015306	Biogenic Monoamines	SLC6A4 protein results in increased import of Biogenic Monoamines analog	28506818
C543008	bis(4-hydroxyphenyl)sulfone	bis(4-hydroxyphenyl)sulfone results in decreased expression of SLC6A4 mRNA	26186136
C006780	bisphenol A	bisphenol A results in increased expression of SLC6A4 mRNA	23146750
C006780	bisphenol A	bisphenol A results in increased expression of SLC6A4 mRNA	23567477
C006780	bisphenol A	bisphenol A affects the expression of SLC6A4 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased expression of SLC6A4 mRNA	26141625
D016642	Bupropion	SLC6A4 polymorphism affects the susceptibility to Bupropion	21658141
D002104	Cadmium	Cadmium binds to SLC6A4 protein mutant form	16272152
D002220	Carbamazepine	[Fluoxetine co-treated with Venlafaxine Hydrochloride co-treated with Carbamazepine] results in decreased expression of SLC6A4 mRNA	22701549
C010063	carbonyl sulfide	carbonyl sulfide results in decreased expression of SLC6A4 mRNA	19395590
D010133	p-Chloroamphetamine	p-Chloroamphetamine results in decreased expression of SLC6A4 mRNA	16054768
D010133	p-Chloroamphetamine	p-Chloroamphetamine results in decreased expression of SLC6A4 protein	16054768
D010133	p-Chloroamphetamine	SLC6A4 protein results in increased susceptibility to p-Chloroamphetamine	10684896
C084597	chlorcyclizine	chlorcyclizine results in increased expression of SLC6A4 mRNA	21058326
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of SLC6A4	17035140
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of SLC6A4 mRNA	18835401
D004390	Chlorpyrifos	Chlorpyrifos results in increased expression of SLC6A4	17035140
D015283	Citalopram	Citalopram binds to and results in decreased activity of SLC6A4 protein	16272152
D015283	Citalopram	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]	17234900
D015283	Citalopram	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]	17234900
D015283	Citalopram	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]	17234900
D015283	Citalopram	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]	17234900
D015283	Citalopram	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]	17234900
D015283	Citalopram	SLC6A4 polymorphism inhibits the reaction [Citalopram affects the secretion of PRL protein]	17000009
D015283	Citalopram	SLC6A4 promoter polymorphism affects the susceptibility to Citalopram	14624186
D015283	Citalopram	[Estradiol co-treated with Progesterone] affects the reaction [SLC6A4 promoter polymorphism affects the reaction [Citalopram results in increased expression of PRL protein]]	21843009
D015283	Citalopram	SLC6A4 promoter affects the reaction [Citalopram results in increased expression of PRL protein]	21843009
D015283	Citalopram	SLC6A4 promoter polymorphism affects the reaction [Citalopram results in increased expression of PRL protein]	21843009
D015283	Citalopram	Citalopram binds to SLC6A4 protein	12672245
D015283	Citalopram	Citalopram results in decreased activity of SLC6A4 protein	14624186
D002997	Clomipramine	Clomipramine binds to and results in decreased activity of SLC6A4 protein	16272152
D002997	Clomipramine	SLC6A4 polymorphism inhibits the reaction [Clomipramine affects the secretion of PRL protein]	17000009
D003024	Clozapine	[SLC6A4 gene polymorphism results in decreased uptake of Serotonin] which results in decreased susceptibility to Clozapine	20452607
D003024	Clozapine	SLC6A4 protein affects the susceptibility to Clozapine	20452607
D003024	Clozapine	Clozapine results in increased expression of SLC6A4	12007678
D003042	Cocaine	Cocaine binds to and results in decreased activity of SLC6A4 protein	16272152
D003042	Cocaine	Cocaine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D003042	Cocaine	Cocaine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D003042	Cocaine	Cocaine results in decreased activity of SLC6A4 protein	18321529
D003042	Cocaine	Cocaine results in increased expression of SLC6A4 protein	11207425
D003042	Cocaine	SLC6A4 mutant form affects the susceptibility to Cocaine	11320258
D003042	Cocaine	Cocaine affects the expression of SLC6A4 mRNA	11072100
D003042	Cocaine	SLC6A4 gene mutant form results in increased susceptibility to Cocaine	20459657
D003042	Cocaine	SLC6A4 results in decreased susceptibility to Cocaine	18581099
D003300	Copper	Copper deficiency results in increased expression of SLC6A4 mRNA	26033743
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of SLC6A4 mRNA	19549813
D016572	Cyclosporine	Cyclosporine results in decreased expression of SLC6A4 mRNA	25562108
C532102	D-161 compound	D-161 compound results in decreased activity of SLC6A4 protein	18561912
D003907	Dexamethasone	Dexamethasone results in increased expression of SLC6A4 protein	16160705
D020372	Dexfenfluramine	Dexfenfluramine affects the activity of SLC6A4 protein	18506000
D003976	Diazinon	Diazinon results in decreased expression of SLC6A4 mRNA	18835401
D003976	Diazinon	Diazinon results in decreased expression of SLC6A4 protein	17035140\|2629760
D003976	Diazinon	Diazinon results in increased expression of SLC6A4 protein	17035140
D019259	Lamivudine	[Lamivudine co-treated with IFNA2 protein] results in increased expression of SLC6A4 mRNA	16476009
D019259	Lamivudine	Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]	16476009
D019259	Lamivudine	Lamivudine results in increased expression of and results in increased activity of SLC6A4 protein	16476009
D019259	Lamivudine	Lamivudine results in increased expression of SLC6A4 mRNA	16476009
D004026	Dieldrin	Dieldrin results in decreased expression of SLC6A4 mRNA	18835401
D004041	Dietary Fats	"Dietary Fats inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of SLC6A4 mRNA]"	22750881
D019422	Dietary Sucrose	Dietary Sucrose results in increased expression of SLC6A4 mRNA	26033743
D015116	5,7-Dihydroxytryptamine	"5,7-Dihydroxytryptamine results in decreased expression of SLC6A4 protein"	16054768
D019813	1,2-Dimethylhydrazine	"1,2-Dimethylhydrazine results in increased expression of SLC6A4 mRNA"	22750881
D019813	1,2-Dimethylhydrazine	"Dietary Fats inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of SLC6A4 mRNA]"	22750881
D007980	Levodopa	[Oxidopamine co-treated with Levodopa] results in increased expression of SLC6A4 protein	20882603
D004298	Dopamine	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]	17234900
D004298	Dopamine	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]	17234900
D004298	Dopamine	SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]	17234900
C074283	estradiol 3-benzoate	estradiol 3-benzoate results in increased expression of SLC6A4 protein	17398000
C074283	estradiol 3-benzoate	Raloxifene Hydrochloride inhibits the reaction [estradiol 3-benzoate results in increased expression of SLC6A4 protein]	17398000
D000431	Ethanol	Ethanol promotes the reaction [mephedrone results in decreased expression of SLC6A4 protein]	26747301
D000431	Ethanol	Ethanol results in decreased expression of SLC6A4 protein	26747301
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of SLC6A4 mRNA	16079270
D005038	Ethylnitrosourea	Ethylnitrosourea results in increased mutagenesis of SLC6A4 gene	16495775
D005456	Fluorescent Dyes	1-phenyl-2-(1-pyrrolidinyl)-1-pentanone inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	"2-(4-bromo-2,5-dimethoxyphenyl)ethylamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
D005456	Fluorescent Dyes	"2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
D005456	Fluorescent Dyes	"2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
D005456	Fluorescent Dyes	4-fluoroamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	4-methoxymethamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	5-(2-aminopropyl)benzofuran inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	Amphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	Cocaine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	Fluoxetine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005456	Fluorescent Dyes	"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
D005456	Fluorescent Dyes	SLC6A4 protein results in increased import of Fluorescent Dyes	28506818
D005473	Fluoxetine	Fluoxetine affects the expression of SLC6A4 protein	16951736
D005473	Fluoxetine	Fluoxetine binds to and results in decreased activity of SLC6A4 protein	16272152
D005473	Fluoxetine	Fluoxetine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]	28506818
D005473	Fluoxetine	Fluoxetine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]	28506818
D005473	Fluoxetine	Fluoxetine results in decreased localization of SLC6A4 protein	17289086
D005473	Fluoxetine	SLC6A4 affects the susceptibility to Fluoxetine	14573314
D005473	Fluoxetine	SLC6A4 gene polymorphism results in decreased susceptibility to Fluoxetine	14604448
D005473	Fluoxetine	SLC6A4 gene polymorphism results in increased susceptibility to Fluoxetine	20010449
D005473	Fluoxetine	SLC6A4 protein affects the susceptibility to Fluoxetine	20010449
D005473	Fluoxetine	SLC6A4 protein results in increased susceptibility to Fluoxetine	14604448
D005473	Fluoxetine	Fluoxetine results in decreased activity of SLC6A4 protein	19616025
D005473	Fluoxetine	Fluoxetine results in increased expression of SLC6A4 mRNA	21083617
D005473	Fluoxetine	[Fluoxetine co-treated with Venlafaxine Hydrochloride co-treated with Carbamazepine] results in decreased expression of SLC6A4 mRNA	22701549
D005473	Fluoxetine	[Estradiol co-treated with Fluoxetine] results in increased expression of SLC6A4 mRNA	21382399
D005473	Fluoxetine	Fluoxetine results in decreased activity of SLC6A4 protein	18561912
D005473	Fluoxetine	Fluoxetine results in decreased expression of SLC6A4 mRNA	15936043\|1698208
D005473	Fluoxetine	[Fluoxetine results in decreased expression of SLC6A4 mRNA] which results in decreased abundance of Serotonin	16982082
D005473	Fluoxetine	Fluoxetine results in decreased expression of SLC6A4 protein	18496518
D005473	Fluoxetine	Org 34850 promotes the reaction [Fluoxetine results in decreased expression of SLC6A4 protein]	18496518
D005473	Fluoxetine	Fluoxetine results in decreased activity of SLC6A4 protein	25766885
D005473	Fluoxetine	Fluoxetine results in decreased expression of SLC6A4	15514160
D005492	Folic Acid	Folic Acid results in decreased expression of SLC6A4 mRNA	25006883
D006220	Haloperidol	Haloperidol results in increased expression of SLC6A4	12007678
C000625835	HFPO2 compound	HFPO2 compound results in increased expression of SLC6A4 mRNA	27553808
C000625836	HFPO4 compound	HFPO4 compound results in increased expression of SLC6A4 mRNA	27553808
D017313	Fenretinide	Fenretinide results in decreased expression of SLC6A4 mRNA	28973697
D012701	Serotonin	Lamivudine promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]	16476009
D012701	Serotonin	Ribavirin promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]	16476009
D012701	Serotonin	Serotonin binds to SLC6A4 protein	16272152
D012701	Serotonin	SLC6A4 gene polymorphism affects the abundance of Serotonin	17203304
D012701	Serotonin	[SLC6A4 gene polymorphism results in decreased uptake of Serotonin] which results in decreased susceptibility to Clozapine	20452607
D012701	Serotonin	SLC6A4 protein promotes the reaction [Serotonin results in increased activity of TAAR1 protein]	17234900
D012701	Serotonin	SLC6A4 protein results in increased uptake of Serotonin	16476009\|2045260
D012701	Serotonin	SLC6A4 protein affects the transport of Serotonin	11223167
D012701	Serotonin	Serotonin results in increased expression of SLC6A4 mRNA	21083617
D012701	Serotonin	SLC6A4 protein results in increased uptake of Serotonin	15972295
D012701	Serotonin	[Fluoxetine results in decreased expression of SLC6A4 mRNA] which results in decreased abundance of Serotonin	16982082
D012701	Serotonin	Serotonin binds to SLC6A4 protein	20204739
D017367	Serotonin Uptake Inhibitors	SLC6A4 intron polymorphism affects the susceptibility to Serotonin Uptake Inhibitors	17018806
D017367	Serotonin Uptake Inhibitors	SLC6A4 promoter affects the susceptibility to Serotonin Uptake Inhibitors	21843009
D017367	Serotonin Uptake Inhibitors	SLC6A4 promoter polymorphism affects the susceptibility to Serotonin Uptake Inhibitors	17018806
D017367	Serotonin Uptake Inhibitors	SLC6A4 promoter polymorphism results in decreased susceptibility to Serotonin Uptake Inhibitors	21843009
D017367	Serotonin Uptake Inhibitors	SLC6A4 protein results in increased susceptibility to Serotonin Uptake Inhibitors	21843009
D017367	Serotonin Uptake Inhibitors	[Sertraline results in decreased expression of SLC6A4 protein] which results in decreased metabolism of Serotonin Uptake Inhibitors	12151556
D006861	Hydrogen Peroxide	Hydrogen Peroxide affects the expression of SLC6A4 mRNA	20044591
D007099	Imipramine	Imipramine results in decreased activity of SLC6A4 protein	18561912
C418119	indatraline	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]	17234900
C418119	indatraline	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]	17234900
C418119	indatraline	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]	17234900
C418119	indatraline	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]	17234900
C418119	indatraline	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]	17234900
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SLC6A4 mRNA	25613284
D007650	Ketanserin	Ketanserin binds to SLC6A4 protein	21871486
D007650	Ketanserin	methamidophos inhibits the reaction [Ketanserin binds to SLC6A4 protein]	21871486
C105748	lubazodone hydrochloride	lubazodone hydrochloride binds to SLC6A4 protein	21823597
C417213	LY 367265	LY 367265 binds to SLC6A4 protein	21823597
C018091	maduramicin	maduramicin results in decreased expression of SLC6A4 mRNA	29128925
D008454	Mazindol	Mazindol binds to and results in decreased activity of SLC6A4 protein	16272152
C548233	mephedrone	Ethanol promotes the reaction [mephedrone results in decreased expression of SLC6A4 protein]	26747301
C548233	mephedrone	mephedrone results in decreased expression of SLC6A4 protein	26747301
C548233	mephedrone	mephedrone results in decreased expression of SLC6A4 protein	25817894
D008627	Mercuric Chloride	Mercuric Chloride results in decreased expression of SLC6A4 mRNA	16507785
D008628	Mercury	SLC6A4 promoter polymorphism affects the susceptibility to Mercury	20526950
C014655	methamidophos	methamidophos inhibits the reaction [Ketanserin binds to SLC6A4 protein]	21871486
D008694	Methamphetamine	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]	17234900
D008694	Methamphetamine	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]]	17234900
D008694	Methamphetamine	Methamphetamine results in decreased expression of SLC6A4 protein	16389202\|1884134
D008694	Methamphetamine	SLC6A4 protein promotes the reaction [Methamphetamine results in increased activity of TAAR1 protein]	17234900
D008694	Methamphetamine	IL6 protein affects the reaction [Methamphetamine affects the expression of SLC6A4 protein]	11093760
D008694	Methamphetamine	Methamphetamine affects the expression of SLC6A4 protein	11093760\|9369336
D008694	Methamphetamine	SLC6A4 mRNA affects the susceptibility to Methamphetamine	19689456
D008694	Methamphetamine	TRP53 protein affects the reaction [Methamphetamine affects the expression of SLC6A4 protein]	9369336
D008694	Methamphetamine	Methamphetamine results in decreased expression of SLC6A4 protein	15900317
D008694	Methamphetamine	SLC6A4 protein results in increased susceptibility to Methamphetamine	10684896
D008694	Methamphetamine	Methamphetamine results in decreased activity of SLC6A4 protein	20722968
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine affects the expression of SLC6A4 protein"	20483717
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine affects the reaction [N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine binds to SLC6A4 protein]"	20483717
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine binds to SLC6A4 protein"	16272152
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Biogenic Monoamines analog]"	28506818
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A4 protein results in increased import of Fluorescent Dyes]"	28506818
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein"	18661256
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein]"	25370842
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 mRNA"	16054768\|1648940
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein"	16054768\|2537084
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"SLC6A4 gene mutant form results in decreased susceptibility to N-Methyl-3,4-methylenedioxyamphetamine"	24595820
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"3-methyladenine inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein]"	26610922
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of SLC6A4 protein"	26610922
D015632	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A4 protein"	20882603
D016686	Monocrotaline	Monocrotaline results in increased expression of SLC6A4 mRNA	17042913
D016686	Monocrotaline	Sertraline inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 mRNA]	17042913
D016686	Monocrotaline	Atorvastatin Calcium inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 protein]	17575010
D016686	Monocrotaline	Monocrotaline results in increased expression of SLC6A4 protein	17575010
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of SLC6A4 mRNA"	25554681
C051752	nefazodone	nefazodone binds to SLC6A4 protein	21823597
D009532	Nickel	Nickel results in decreased expression of SLC6A4 mRNA	18835401
C028007	nickel monoxide	nickel monoxide results in decreased expression of SLC6A4 mRNA	19167457
C011386	nisoxetine	nisoxetine binds to and results in decreased activity of SLC6A4 protein	16272152
C007350	nitrofen	nitrofen results in increased expression of SLC6A4 protein	24888825\|2507842
C420885	N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine	"N-Methyl-3,4-methylenedioxyamphetamine affects the reaction [N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine binds to SLC6A4 protein]"	20483717
C420885	N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine	"N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine binds to SLC6A4 protein"	20483717
D009627	Nomifensine	Nomifensine binds to and results in decreased activity of SLC6A4 protein	16272152
D009638	Norepinephrine	SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]	17234900
D009661	Nortriptyline	SLC6A4 gene polymorphism results in decreased susceptibility to Nortriptyline	14604448
D009661	Nortriptyline	SLC6A4 polymorphism affects the susceptibility to Nortriptyline	21658141
D009661	Nortriptyline	SLC6A4 promoter polymorphism affects the susceptibility to Nortriptyline	17018806
D009661	Nortriptyline	SLC6A4 protein results in increased susceptibility to Nortriptyline	14604448
D009655	Octopamine	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]	17234900
D009655	Octopamine	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]]	17234900
D009655	Octopamine	SLC6A4 protein promotes the reaction [Octopamine results in increased activity of TAAR1 protein]	17234900
D016627	Oxidopamine	[Oxidopamine co-treated with Levodopa] results in increased expression of SLC6A4 protein	20882603
D017371	8-Hydroxy-2-(di-n-propylamino)tetralin	SLC6A4 results in increased susceptibility to 8-Hydroxy-2-(di-n-propylamino)tetralin	18581099
C526063	Org 34850	Org 34850 promotes the reaction [Fluoxetine results in decreased expression of SLC6A4 protein]	18496518
C030110	oxaliplatin	[oxaliplatin co-treated with Topotecan] results in increased expression of SLC6A4 mRNA	25729387
D010126	Ozone	Ozone affects the expression of SLC6A4 protein	23570994
D010278	Parathion	Parathion affects the expression of SLC6A4 protein	18773955
D010278	Parathion	Parathion results in decreased expression of SLC6A4 protein	19616088
D010278	Parathion	Parathion results in increased expression of SLC6A4 protein	19616088\|2001545
D017374	Paroxetine	Paroxetine binds to and results in decreased activity of SLC6A4 protein	16272152
D017374	Paroxetine	Paroxetine results in decreased expression of SLC6A4 mRNA	16055263
D017374	Paroxetine	Paroxetine affects the expression of SLC6A4 mRNA	10575045
D017374	Paroxetine	Paroxetine results in decreased expression of SLC6A4 mRNA	10575045
C417083	peginterferon alfa-2b	SLC6A4 promoter polymorphism promotes the reaction [IL6 promoter SNP results in decreased susceptibility to peginterferon alfa-2b]	18458677
C417083	peginterferon alfa-2b	SLC6A4 promoter polymorphism results in decreased susceptibility to peginterferon alfa-2b	18458677
C029261	phenethylamine	SLC6A4 protein promotes the reaction [phenethylamine results in increased activity of TAAR1 protein]	17234900
D010879	Piperazines	Piperazines analog binds to SLC6A4 protein	11931612
C006253	pirinixic acid	pirinixic acid results in decreased expression of SLC6A4 mRNA	17426115
C006253	pirinixic acid	pirinixic acid results in increased expression of SLC6A4 mRNA	18301758
C006253	pirinixic acid	pirinixic acid results in decreased expression of SLC6A4 mRNA	19162173
D011374	Progesterone	[Estradiol co-treated with Progesterone] affects the reaction [SLC6A4 promoter polymorphism affects the reaction [Citalopram results in increased expression of PRL protein]]	21843009
D011738	Pyrilamine	Pyrilamine analog binds to SLC6A4 protein	11931612
D011794	Quercetin	Quercetin results in decreased expression of SLC6A4 mRNA	21632981
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride affects the expression of SLC6A4 mRNA	16079270
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride inhibits the reaction [estradiol 3-benzoate results in increased expression of SLC6A4 protein]	17398000
D012110	Reserpine	Reserpine results in decreased expression of SLC6A4 mRNA	10027743
D012254	Ribavirin	Ribavirin promotes the reaction [SLC6A4 protein results in increased uptake of Serotonin]	16476009
D012254	Ribavirin	Ribavirin results in increased expression of and results in increased activity of SLC6A4 protein	16476009
D012254	Ribavirin	Ribavirin results in increased expression of SLC6A4 mRNA	16476009
D020280	Sertraline	Sertraline inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 mRNA]	17042913
D020280	Sertraline	SLC6A4 promoter polymorphism results in increased susceptibility to Sertraline	12955294
D020280	Sertraline	SLC6A4 protein affects the susceptibility to Sertraline	12955294
D020280	Sertraline	Sertraline results in decreased expression of SLC6A4 protein	18923402
D020280	Sertraline	[Estradiol co-treated with Sertraline] affects the expression of SLC6A4 mRNA	18650020
D020280	Sertraline	Estradiol promotes the reaction [Sertraline results in increased expression of SLC6A4 mRNA]	18650020
D020280	Sertraline	Sertraline results in decreased expression of SLC6A4 protein	12151556
D020280	Sertraline	[Sertraline results in decreased expression of SLC6A4 protein] which results in decreased metabolism of Serotonin Uptake Inhibitors	12151556
D020280	Sertraline	Sertraline results in increased expression of SLC6A4 mRNA	18650020
D019821	Simvastatin	Simvastatin results in increased activity of SLC6A4 protein	15740995
D013750	Tetrachloroethylene	Tetrachloroethylene results in increased expression of SLC6A4 mRNA	28973375
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SLC6A4 mRNA	25613284
C050504	tianeptine	tianeptine binds to and results in decreased activity of SLC6A4 protein	16272152
C009495	titanium dioxide	titanium dioxide results in decreased expression of SLC6A4 mRNA	23557971
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution affects the expression of SLC6A4 mRNA	20133372
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of SLC6A4 mRNA	19969065
D019772	Topotecan	[oxaliplatin co-treated with Topotecan] results in increased expression of SLC6A4 mRNA	25729387
D019772	Topotecan	Topotecan results in increased expression of SLC6A4 mRNA	25729387
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of SLC6A4 mRNA"	26179874
C030820	tryptamine	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]	17234900
C030820	tryptamine	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]]	17234900
C030820	tryptamine	SLC6A4 protein promotes the reaction [tryptamine results in increased activity of TAAR1 protein]	17234900
D014439	Tyramine	Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]	17234900
D014439	Tyramine	indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]]	17234900
D014439	Tyramine	SLC6A4 protein promotes the reaction [Tyramine results in increased activity of TAAR1 protein]	17234900
D014520	Urethane	Urethane results in decreased expression of SLC6A4 mRNA	28818685
D014640	Vancomycin	Vancomycin results in increased expression of SLC6A4 mRNA	18930951
D000069470	Venlafaxine Hydrochloride	SLC6A4 gene polymorphism affects the susceptibility to Venlafaxine Hydrochloride	17503984
D000069470	Venlafaxine Hydrochloride	[Fluoxetine co-treated with Venlafaxine Hydrochloride co-treated with Carbamazepine] results in decreased expression of SLC6A4 mRNA	22701549
C557874	vortioxetine	vortioxetine binds to and results in decreased activity of SLC6A4 protein	21486038
C557874	vortioxetine	vortioxetine binds to and results in decreased activity of SLC6A4 protein	21486038
D015032	Zinc	Zinc deficiency results in decreased expression of SLC6A4 mRNA	16140947
D015032	Zinc	Zinc deficiency results in increased expression of SLC6A4 mRNA	16413754
D015032	Zinc	Zinc inhibits the reaction [Zinc deficiency results in decreased expression of SLC6A4 mRNA]	16140947

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005215	transporter activity	-	IBA	21873635
GO:0005335	serotonin:sodium symporter activity	-	IDA	8987735
GO:0005335	serotonin:sodium symporter activity	-	IMP	19270731
GO:0005335	serotonin:sodium symporter activity	-	TAS	-
GO:0005515	protein binding	-	IPI	11343649 12177201 16870614 16882008 19270731
GO:0008504	monoamine transmembrane transporter activity	-	IDA	16024787
GO:0015222	serotonin transmembrane transporter activity	-	IBA	21873635
GO:0015222	serotonin transmembrane transporter activity	-	IDA	8987735
GO:0015222	serotonin transmembrane transporter activity	-	IMP	19270731
GO:0017022	myosin binding	-	IEA	-
GO:0017075	syntaxin-1 binding	-	IEA	-
GO:0017137	Rab GTPase binding	-	IPI	18227069
GO:0019811	cocaine binding	-	IEA	-
GO:0042803	protein homodimerization activity	-	IEA	-
GO:0046872	metal ion binding	-	IEA	-
GO:0050998	nitric-oxide synthase binding	-	IEA	-
GO:0051015	actin filament binding	-	ISS	-
GO:0051378	serotonin binding	-	IBA	21873635

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001666	response to hypoxia	-	IEA	-
GO:0006837	serotonin transport	-	IDA	19270731
GO:0007584	response to nutrient	-	IEA	-
GO:0007613	memory	-	IEA	-
GO:0007623	circadian rhythm	-	IEA	-
GO:0009636	response to toxic substance	-	IDA	17575980
GO:0010628	positive regulation of gene expression	-	IEA	-
GO:0014064	positive regulation of serotonin secretion	-	IEA	-
GO:0015844	monoamine transport	-	IDA	16024787
GO:0021941	negative regulation of cerebellar granule cell precursor proliferation	-	IEA	-
GO:0032227	negative regulation of synaptic transmission, dopaminergic	-	IEA	-
GO:0032355	response to estradiol	-	IEA	-
GO:0035176	social behavior	-	ISS	-
GO:0035725	sodium ion transmembrane transport	-	IBA	21873635
GO:0042136	neurotransmitter biosynthetic process	-	TAS	-
GO:0042310	vasoconstriction	-	IEA	-
GO:0042713	sperm ejaculation	-	IEA	-
GO:0045665	negative regulation of neuron differentiation	-	IEA	-
GO:0045787	positive regulation of cell cycle	-	IEA	-
GO:0046621	negative regulation of organ growth	-	ISS	-
GO:0048854	brain morphogenesis	-	ISS	-
GO:0051259	protein complex oligomerization	-	ISS	-
GO:0051260	protein homooligomerization	-	IEA	-
GO:0051610	serotonin uptake	-	IBA	21873635
GO:0051610	serotonin uptake	-	IDA	8987735 16870614 17506858 18227069 19270731
GO:0051610	serotonin uptake	-	IMP	7681602
GO:0055085	transmembrane transport	-	IEA	-
GO:0071300	cellular response to retinoic acid	-	IEA	-
GO:0071321	cellular response to cGMP	-	IEA	-
GO:0090067	regulation of thalamus size	-	IMP	18378990

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005829	cytosol	-	IDA	19270731
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005886	plasma membrane	-	IDA	16870614 17506858 18227069 19270731
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IC	19270731
GO:0010008	endosome membrane	-	IEA	-
GO:0012505	endomembrane system	-	IDA	17506858 18227069
GO:0043005	neuron projection	-	IBA	21873635
GO:0045121	membrane raft	-	IDA	16870614
GO:0098793	presynapse	-	IEA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-112311	Neurotransmitter clearance	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-380615	Serotonin clearance from the synaptic cleft	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
20838391	Functional genetic variants that increase synaptic serotonin and 5-HT3 receptor sensitivity predict alcohol and drug dependence. (2011 Nov)	Enoch MA	Mol Psychiatry
20192950	Variation in the gene encoding the serotonin transporter is associated with a measure of sociopathy in alcoholics. (2011 Jan)	Herman AI	Addict Biol
18690118	Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. (2008 Sep)	Perkins KA	Behav Pharmacol
16497275	Low level of response to alcohol as associated with serotonin transporter genotype and high alcohol intake in adolescents. (2006 Aug 1)	Hinckers AS	Biol Psychiatry
22925276	Modifying the role of serotonergic 5-HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study. (2012 Nov)	Nielsen DA	Genes Brain Behav
27619010	PTSD, alcohol dependence, and conduct problems: Distinct pathways via lability and disinhibition. (2017 Jan)	Simons JS	Addict Behav
26311211	Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy. (2016 Mar)	Thompson MD	Alcohol Alcohol
26227246	Susceptibility loci for heroin and cocaine addiction in the serotonergic and adrenergic pathways in populations of different ancestry. (2015)	Levran O	Pharmacogenomics
19170664	Association between Val66Met brain-derived neurotrophic factor (BDNF) gene polymorphism and post-treatment relapse in alcohol dependence. (2009 Apr)	Wojnar M	Alcohol Clin Exp Res
21778150	A preliminary analysis of interactions between genotype, retrospective ADHD symptoms, and initial reactions to smoking in a sample of young adults. (2012 Feb)	Bidwell LC	Nicotine Tob Res
19179283	Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes. (2009 Feb 10)	Carneiro AM	Proc Natl Acad Sci U S A
18690117	Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers. (2008 Sep)	Perkins KA	Behav Pharmacol
12351926	Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. (2002 Sep)	Kranzler H	Alcohol Clin Exp Res
12218658	Antisocial alcoholism and serotonin-related polymorphisms: association tests. (2002 Sep)	Hill EM	Psychiatr Genet
25655461	Clinically relevant genetic biomarkers from the brain in alcoholism with representation on high resolution chromosome ideograms. (2015 Apr 15)	Manzardo AM	Gene
23287538	Alcohol intoxications during adolescence increase motivation for alcohol in adult rats and induce neuroadaptations in the nucleus accumbens. (2013 Apr)	Alaux-Cantin S	Neuropharmacology
23290502	Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both European American and African American smokers. (2013 May 1)	Yang Z	Drug Alcohol Depend
25770138	Alcohol dependence and serotonin transporter functional polymorphisms 5-HTTLPR and rs25531 in an Italian population. (2015 May)	Pascale E	Alcohol Alcohol
19995670	Preliminary effects of bupropion and the promoter region (HTTLPR) serotonin transporter (SLC6A4) polymorphism on smoking behavior in schizophrenia. (2010 Jan 30)	Bloch B	Psychiatry Res
23149035	Association study of serotonin transporter availability and SLC6A4 gene polymorphisms in patients with major depression. (2013 Jun 30)	Ho PS	Psychiatry Res
19885717	Serotonin transporter promoter polymorphism and dopaminergic sensitivity in alcoholics. (2010 Jan)	Budde H	J Neural Transm (Vienna)
21906503	Different phenotypic and genotypic presentations in alcohol dependence: age at onset matters. (2011 Sep)	Chen YC	J Stud Alcohol Drugs
9627746	Serotonin transporter gene variants in alcohol-dependent subjects with dissocial personality disorder. (1998 Jun 15)	Sander T	Biol Psychiatry
28884473	Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. (2017 Sep 8)	Schuit E	Cochrane Database Syst Rev
16702982	The serotonin transporter gene polymorphism is not associated with smoking behavior. (2006 Nov-Dec)	Trummer O	Pharmacogenomics J
23518607	Multi-cultural association of the serotonin transporter gene (SLC6A4) with substance use disorder. (2013 Aug)	Cao J	Neuropsychopharmacology
16766085	GABA(A) receptor beta isoform protein expression in human alcoholic brain: interaction with genotype. (2006 Nov)	Buckley ST	Neurochem Int
22933845	Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse. (2012 Jun)	Herman AI	Subst Abuse Rehabil
29325449	Analysis of DNA Methylation in Young People: Limited Evidence for an Association Between Victimization Stress and Epigenetic Variation in Blood. (2018 Jan 12)	Marzi SJ	Am J Psychiatry
15112932	Biological and behavioral markers of alcohol sensitivity. (2004 Feb)	Fromme K	Alcohol Clin Exp Res
17123474	Genetic and environmental predictors of early alcohol use. (2007 Jun 1)	Kaufman J	Biol Psychiatry
18188752	Interactions between genotype and retrospective ADHD symptoms predict lifetime smoking risk in a sample of young adults. (2008 Jan)	McClernon FJ	Nicotine Tob Res
19033200	Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. (2008 Dec 2)	Baganz NL	Proc Natl Acad Sci U S A
20598814	A serotonin transporter polymorphism (5-HTTLPR) predicts the development of adolescent alcohol use. (2010 Nov 1)	van der Zwaluw CS	Drug Alcohol Depend
28192769	Disorganization at the stage of schizophrenia clinical outcome: Clinical-biological study. (2017 May)	Nestsiarovich A	Eur Psychiatry
21852976	The Serotonin Transporter Polymorphism (5-HTTLPR) and Alcohol Problems in Heavy Drinkers: Moderation by Depressive Symptoms. (2011)	Tartter MA	Front Psychiatry
24773166	Ondansetron reduces naturalistic drinking in nontreatment-seeking alcohol-dependent individuals with the LL 5'-HTTLPR genotype: a laboratory study. (2014 Jun)	Kenna GA	Alcohol Clin Exp Res
20981038	Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. (2011 Jan)	Ishii T	J Hum Genet
24781734	Social isolation-induced epigenetic changes in midbrain of adult mice. (2014 Apr)	Siuda D	J Physiol Pharmacol
24220019	Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. (2014 Aug)	Enoch MA	Pharmacol Biochem Behav
22545912	Association of genetic, psychological and behavioral factors with sleep bruxism in a Japanese population. (2012 Jun)	Abe Y	J Sleep Res
21658141	Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. (2012 Jan)	Quaak M	Addiction
23757001	Association, interaction, and replication analysis of genes encoding serotonin transporter and 5-HT3 receptor subunits A and B in alcohol dependence. (2013 Oct)	Seneviratne C	Hum Genet
21626393	Association between the STin2 VNTR polymorphism and smoking behavior in oral cancer patients and healthy individuals. (2012 Mar)	de Lima KW	Clin Exp Med
26352193	Alcohol Dependence and Genetic Variability in the Serotonin Pathway among Currently and Formerly Alcohol-Dependent Males. (2015)	Plemenitas A	Neuropsychobiology
19759277	Impact of tryptophan metabolism on the vulnerability to alcohol-related blackouts and violent impulsive behaviours. (2010 Jan-Feb)	Vignau J	Alcohol Alcohol
14506400	Alleles of a functional serotonin transporter promoter polymorphism are associated with major depression in alcoholics. (2003 Sep)	Nellissery M	Alcohol Clin Exp Res
15654505	Association of habitual smoking and drinking with single nucleotide polymorphism (SNP) in 40 candidate genes: data from random population-based Japanese samples. (2005)	Liu Y	J Hum Genet
29333880	Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. (2018)	Crist RC	Am J Drug Alcohol Abuse
17987668	The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. (2008 Jul 5)	Philibert RA	Am J Med Genet B Neuropsychiatr Genet
25710844	A meta-analysis of the associations between the SLC6A4 promoter polymorphism (5HTTLPR) and the risk for alcohol dependence. (2015 Apr)	Villalba K	Psychiatr Genet
23766378	Association between promoter methylation of serotonin transporter gene and depressive symptoms: a monozygotic twin study. (2013 Jul-Aug)	Zhao J	Psychosom Med
11236836	Genetic determinants of alcohol addiction and metabolism: a survey in Italy. (2001 Feb)	Pastorelli R	Alcohol Clin Exp Res
22290534	Promoter methylation of serotonin transporter gene is associated with obesity measures: a monozygotic twin study. (2013 Jan)	Zhao J	Int J Obes (Lond)
15630511	A functional serotonin transporter (SLC6A4) polymorphism modifies the association of smoking and diabetes with asymptomatic carotid atherosclerosis. (2005 Jan)	Wolff B	Thromb Haemost
25288136	Genome-wide meta-analysis identifies six novel loci associated with habitual coffee consumption. (2015 May)	Cornelis MC	Mol Psychiatry
20868372	Perinatal risk factors interacting with catechol O-methyltransferase and the serotonin transporter gene predict ASD symptoms in children with ADHD. (2010 Nov)	Nijmeijer JS	J Child Psychol Psychiatry
19884608	Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. (2009 Nov)	Xie P	Arch Gen Psychiatry
18552399	Association between the Stin2 VNTR polymorphism of the serotonin transporter gene and treatment outcome in alcohol-dependent patients. (2008 Sep-Oct)	Florez G	Alcohol Alcohol
24796636	Differential impact of serotonin transporter activity on temperament and behavior in persons with a family history of alcoholism in the Oklahoma Family Health Patterns Project. (2014 Jun)	Lovallo WR	Alcohol Clin Exp Res
23897038	Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. (2013 Sep)	Johnson BA	Am J Psychiatry
24892317	Genetic variants associated with addictive behavior in Colombian addicted and non-addicted to heroin or cocaine. (2013 Jan)	Isaza C	Colomb Med (Cali)
29162172	Cumulative prenatal exposure to adversity reveals associations with a broad range of neurodevelopmental outcomes that are moderated by a novel, biologically informed polygenetic score based on the serotonin transporter solute carrier family C6, member 4 (SLC6A4) gene expression. (2017 Dec)	Silveira PP	Dev Psychopathol